secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0000950170-24-044424
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Intellia appoints Michael P. Dube as principal accounting officer
-----------------------------------------------------------------

- Michael P. Dube, 46, appointed as principal accounting officer; currently VP and Chief Accounting Officer.
- Dube joined Intellia in September 2023; previously Global Corporate Controller at Abiomed (2012-2023).
- Dube is a CPA with 10 years at Deloitte & Touche in audit and assurance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024044424/0000950170-24-044424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024044424/ntla-20240410.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer